GlassScriptPhysician profile
Janet R Reiser
NPI 1942270947
$5,795.59
in general payments reported to CMS, 2019-2025
29 companies · $465 in 2025
The $465 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,902 · 2020: $442 · 2021: $626 · 2022: $769 · 2023: $1,284 · 2024: $308 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,756.89 | 2019-2023 | |
| Romark Laboratories, Lc | $824.00 | 2019 | |
| Janssen Biotech, INC. | $436.72 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $387.51 | 2022-2023 | Dupixent |
| Boston Scientific Corporation | $358.43 | 2024-2025 | General - Hemostasis, Apollo Esg System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.69 | 2019-2023 | Xifaxan |
| Pfizer INC. | $273.42 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $245.21 | 2022-2023 | Zeposia |
| Celgene Corporation | $147.50 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $144.22 | 2024 | Rezdiffra |
| Merck Sharp & Dohme LLC | $119.78 | 2019-2021 | |
| Dova Pharmaceuticals | $112.92 | 2019 | |
| Gilead Sciences, INC. | $112.72 | 2019-2021 | |
| Genzyme Corporation | $89.82 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.26 | 2019-2023 | Entyvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $76.63 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $69.85 | 2020-2021 | |
| Medtronic, INC. | $55.31 | 2023 | Nexpowder |
| Allergan, INC. | $37.26 | 2019 | |
| Ethicon US, LLC | $19.91 | 2020 | |
| Axonics, INC. | $17.36 | 2021 | |
| Daiichi Sankyo INC. | $14.61 | 2019 | |
| Qol Medical, LLC | $13.95 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.60 | 2022 | |
| Janssen Scientific Affairs, LLC | $12.97 | 2019 | |
| Alfasigma USA, INC. | $12.34 | 2022 | |
| Shire North American Group INC | $11.49 | 2019 | |
| Braintree Laboratories, INC. | $11.22 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$274,993.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Reiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.